Stock Events

Argen X 

€362
2
-€6-1.63% Wednesday 07:09

Statistics

Day High
362
Day Low
362
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
13.51B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-4.83
-3.22
-1.61
0
Expected EPS
-1.52
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1AEA.F. It's not an investment recommendation.

About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Show more...
CEO
Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA
Employees
336
Country
NL
ISIN
US04016X1019
WKN
000A2H9WD

Listings